These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 991465)

  • 1. The use of hydroxy-DL-proline-2-(14)C in the investigation of hydroxyproline metabolism in normal subjects and in patients with renal insufficiency.
    Hart W; van den Hamer CJ; van der Sluys Veer J
    Clin Nephrol; 1976 Sep; 6(3):379-87. PubMed ID: 991465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Animal experiments on the relationship between urinary excretion of hydroxyproline and serum hydroxyproline fractions].
    Morsches B
    Hautarzt; 1976 May; 27(5):234-42. PubMed ID: 955890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The plasma concentration and renal elimination of phenols in patients with chronic renal insufficiency.
    Schück O; Vidláková M; Erben J; Nádvorniková H; Teplan V; Reitschlägerová V
    Czech Med; 1989; 12(2):117-24. PubMed ID: 2504560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics of biosynthetic human proinsulin in patients with terminal renal insufficiency.
    Zilker TR; Rebel C; Kopp KF; Wahl K; Ermler R; Heinzel G; Hales CN; Bottermann P
    Horm Metab Res Suppl; 1988; 18():43-8. PubMed ID: 3056810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The hydroxyproline content of plasma of patients with impaired renal function.
    Hart W; Duursma SA; Visser WJ; Njio LK
    Clin Nephrol; 1975; 4(3):104-8. PubMed ID: 1183097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacokinetics of cefotaxime in patients with chronic renal impairment (author's transl)].
    Fillastre JP; Ings RM; Leroy A; Humbert G; Godin M
    Nouv Presse Med; 1981 Feb; 10(8):574-9. PubMed ID: 6259595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of zopiclone pharmacokinetics in patients with impaired renal function and normal subjects. Effect of hemodialysis.
    Marc-Aurele J; Caille G; Bourgoin J
    Sleep; 1987; 10 Suppl 1():22-6. PubMed ID: 3438644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyproline metabolism in type II hyperprolinaemia.
    Similä S
    Ann Clin Biochem; 1979 Jul; 16(4):177-81. PubMed ID: 533224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
    Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
    Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of buflomedil after intravenous administration in patients with chronic renal failure.
    Rey E; d'Athis P; Richard MO; Fillastre JP; Olive G
    Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):648-52. PubMed ID: 6526539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacokinetics of cefotaxime and metabolites in uremic patients (author's transl)].
    Fillastre JP; Ings RM; Leroy A; Godin M; Humbert G
    Nephrologie; 1982; 3(1):12-8. PubMed ID: 6283411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The presence of a natriuretic factor in urine of patients with chronic uremia. The absence of the factor in nephrotic uremic patients.
    Bourgoignie JJ; Hwang KH; Ipakchi E; Bricker NS
    J Clin Invest; 1974 Jun; 53(6):1559-67. PubMed ID: 4830222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic effects of keto acid--amino acid supplementation in patients with chronic renal insufficiency receiving a low-protein diet and recombinant human erythropoietin--a randomized controlled trial.
    Teplan V; Schück O; Votruba M; Poledne R; Kazdová L; Skibová J; Malý J
    Wien Klin Wochenschr; 2001 Sep; 113(17-18):661-9. PubMed ID: 11603100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of ofloxacin in healthy subjects and patients with varying degrees of renal impairment.
    Flor S; Guay D; Opsahl J; Tack K; Matzke G
    Int J Clin Pharmacol Res; 1991; 11(3):115-21. PubMed ID: 1809697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infusion of radiocontrast agents induces exaggerated release of urinary endothelin in patients with impaired renal function.
    Fujisaki K; Kubo M; Masuda K; Tokumoto M; Hirakawa M; Ikeda H; Matsui R; Matsuo D; Fukuda K; Kanai H; Hirakata H; Iida M
    Clin Exp Nephrol; 2003 Dec; 7(4):279-83. PubMed ID: 14712357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition kinetics of dibekacin in normal subjects and in patients with renal failure.
    Arancibia A; Chávez J; Ibarra R; Ruiz I; Icarte A; Thambo S; Chávez H
    Int J Clin Pharmacol Ther Toxicol; 1987 Jan; 25(1):38-43. PubMed ID: 3557728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of ceftriaxone in subjects with renal insufficiency.
    Kowalsky SF; Echols RM; Parker MA
    Clin Pharm; 1985; 4(2):177-81. PubMed ID: 3987216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic clearance of recombinant human growth hormone in health and chronic renal failure.
    Haffner D; Schaefer F; Girard J; Ritz E; Mehls O
    J Clin Invest; 1994 Mar; 93(3):1163-71. PubMed ID: 8132756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.